Bayer Deal History & Licensing Activity
Bayer is a large pharma headquartered in Germany. Over the past three years, Bayer has been involved in 10 licensing and acquisition transactions, with a primary focus on Other (4 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
9
Active Trials
50
Top Modality
Other
Focus Area
Solid Tumors
Bayer Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Bayer in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Eye implant for glaucoma and diabetic retinopathy | Perfuse Therapeutics | Other | Unknown | acquisition | May 28, 2026 |
| eye implant for glaucoma/diabetic retinopathy | Perfuse Therapeutics | Other | Preclinical | acquisition | May 23, 2026 |
| AB-1009 | Genethon | Gene Therapy | Phase 1 |
Bayer Pipeline Focus
Therapeutic areas and modalities where Bayer is most active based on deal history and clinical trial data.
Therapeutic Areas
Bayer Strategic Signals
Key indicators of Bayer's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Bayer Clinical Pipeline
Bayer has 50 active clinical trials across 6 development phases.
19
Unknown
3
Phase 4
4
Not Applicable
6
Phase 1
8
Phase 2
10
Phase 3
See How Your Asset Matches Bayer's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Cardiovascular Deal Benchmarks
Market sizing, deal terms, and competitive landscape for cardiovascular
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Bayer Licensing & Deal Activity
Bayer is a large pharma company based in Germany that has been actively engaged in licensing transactions across the biopharma landscape. With 10 deals over the past three years, Bayer ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Bayer include Solid Tumors (14 deals and trials), Cardiovascular (13 deals and trials), Metabolic (11 deals and trials), and Oncology (3 deals and trials). In terms of modality, Bayer has shown particular interest in other, small molecules, gene therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Bayer and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Bayer's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.